𝗙𝗲𝗯𝗿𝘂𝗮𝗿𝘆 𝟮𝟬𝟮𝟲 𝗢𝘂𝘁𝗹𝗼𝗼𝗸: 𝗞𝗲𝘆 𝗙𝗗𝗔 𝗣𝗗𝗨𝗙𝗔 𝗠𝗶𝗹𝗲𝘀𝘁𝗼𝗻𝗲𝘀 𝗦𝗵𝗮𝗽𝗶𝗻𝗴 𝗕𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮 We analyze the science, competitive dynamics & strategic implications so you stay ahead #PDUFA #FDA #Biopharma #RareDisease #Oncology #DrugApproval #Biotech

We’re pleased to share that Himanshu Sehgal (Octavus Consulting), Expert Speaker at SAMPRABHAV-2026 at Dept. Of Pharmaceutical Management,NIPER SAS Nagar. 🗓️8th Feb, 26 | Day 2 #OctavusConsulting #SAMPRABHAV2026 #NIPERMohali #ExpertTalk #HealthcareConsulting #LifeSciences

From KOLs to DOLs in cardiology Influence isn’t just journals & conferences now. It’s also YouTube, X, and Instagram shaping how doctors and patients learn about the heart 📩 [email protected] #KOL #DOL #OctavusConsulting

Octavus Consulting is heading to 23rd BioAsia 2026 🚀 Our Partner Himanshu Sehgal will be at #BioAsia to discuss AI, data & innovation shaping Life Sciences and Biopharma. Let’s connect:- [email protected] #TechBio #HealthcareInnovation #OctavusConsulting

#MedTechM&A Alert: Boston Scientific to acquire Penumbra, Inc. in a ~$14.5B cash & stock deal ($374/share), boosting its vascular & cardiovascular portfolio (thrombectomy, stroke, DVT, PE). Penumbra: ~$1.4B FY25 rev, high‑teens growth. Deals window: Feb’25–Jan’26 #OctavusConsulting

Our Feb 2026 - Part 1 Edition is live! Explore the latest global healthcare updates, from clinical milestones and regulatory shifts to strategic partnerships. 📩[email protected] Subscribe for bi-weekly updates linkedin.com/newsletters/74… #OctavusConsulting #LifeSciences

At the JPMorgan Healthcare Conference, China biotech signaled a big shift. From manufacturing scale to global innovation leadership. Rising pipelines, US investor interest & cross-border partnerships ahead. Full insights + report: octavusconsulting.com/china-biotechs… #JPMHealthcare2026

US/EU Regulatory Spotlight: (Nov’25–Jan’26): New approvals, VOYXACT (IgAN), MYQORZO (oHCM) & INLURIYO (BC), shine a light on rare diseases, cardiology & oncology. Recalls hit famotidine & atorvastatin, while FDA/EMA reforms ease RWE and CGT pathways. Innovation is accelerating!

Nephrology & Urology markets are evolving fast 📈 Top 3Q’25 performers: MYRBETRIQ ($848M), KERENDIA ($259M), JYNARQUE ($245M) Growth driven by CKD, OAB & rare renal therapies - with innovation shaping 2026 outlook 🚀 #Nephrology #Urology #PharmaTrends #MarketInsights

Biosimilars are no longer a “nice-to-have”; they’re becoming a core pillar of healthcare. At the intersection of science, cost & access, a ~$200B opportunity + patent cliff + faster regulations are set to reshape specialty care. #Biosimilar #Interchangeability #Healthcare

Regulatory momentum in #Nephrology & #Urology continues in Q1 2026! Priority & Fast Track designations spotlight innovation in #IgAN, #RCC, #ProstateCancer & #mUC therapies. Agencies accelerate breakthroughs addressing unmet renal & urologic needs #RegulatoryAffairs #LifeSciences

Our Mar 16-31, 2026 Part 2 Edition is Live! Q2W Highlights update, a packed stretch of global clinical, regulatory, and deal activity across biopharma. 📩[email protected] #HealthcareTrends #HealthcareFuture #Q2WUpdates #IndustryInsights #AI linkedin.com/pulse/q2w-news…

Key #PDUFA dates this Apr'26! Watch for FDA decisions on major drugs: Orca‑T, RP1 + Nivolumab, Filspari, Sarclisa SC & GTx‑104, Dupixent, MK‑8591A, Tzield, and AXS‑05. Big month for #Pharma #Biotechinnovation #FDAApprovals #DrugPipeline

🚀 Neurology innovation shaping Q4 2025! Blockbusters like OCREVUS, VYVGART & KESIMPTA drive growth and redefine CNS care. The future lies in impactful, accessible, patient‑centric therapies. #Neurology #Pharma #CNS #Innovation #OctavusConsulting

💊Lilly is acquiring Centessa for up to $7.8B to secure its OX2R agonist portfolio, led by cleminorexton for NT1, NT2, and IH. Deal is heavily CVR‑weighted, with the richest payout tied to IH where diagnosis, trial design and endpoints are still evolving. #BiopharmaDeals #Orexin

Cell therapy is shifting from experimental to investable, driven by curative potential, oncology expansion, rising trials, scalable manufacturing, and big-pharma backing. It’s fast becoming a core pillar of CGT, with 2026 shaping up as a major catalyst year. #CellTherapy #CGT

April 2026 (Part 1) is live! Explore key healthcare trends as regulation, capital, and technology reshape life sciences. Stay tuned for our upcoming Q2W updates. 📩 Reach out at [email protected] #HealthcareInnovation #LifeSciences #MedTech #AI linkedin.com/pulse/q2w-news…

ASOs are emerging as a key modality in genetic medicine, offering precision targeting and flexible RNA mechanisms. Despite delivery and cost challenges and rising competition from RNAi and gene editing. Connect: [email protected] #RNAi #GeneEditing #NucleicAcidTherapeutics

𝗦𝗼𝗺𝗲𝘁𝗵𝗶𝗻𝗴 𝗯𝗶𝗴 𝗶𝘀 𝗰𝗼𝗺𝗶𝗻𝗴... 👀 #StayTuned #HealthcareInnovation #AI #ThoughtLeadership #ComingSoon #webinar #OctavusConsulting #BusinessConsulting #HealthcareLeaders #HealthcareNoida #HospitalManagement #MedicalConsulting #DigitalHealth

The acquisition of KashivBio by Amneal Pharmaceuticals isn’t just another deal, it’s a market signal. A $300B+ biologics LOE wave is coming, and the biosimilars race is accelerating. #Biosimilars #Pharma #Biologics #Healthcare #PharmaStrategy #MergersAndAcquisitions #Biotech